Accordingly, CD133+CXCR4+ OVCAR5 sorted cells were evaluated for sensitivity to cisplatin, a commonly used agent for the treatment of ovarian cancer, and for the expression of ABCG2, a surface transporter associated with resistance to chemotherapy. This evidence concerns the gene ABCG2 and ovarian cancer.